PRESS RELEASE published on 08/15/2023 at 07:25, 3 years 2 months ago Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
PRESS RELEASE published on 07/18/2023 at 12:26, 3 years 3 months ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 06/30/2023 at 07:15, 3 years 4 months ago Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
PRESS RELEASE published on 06/26/2023 at 17:31, 3 years 4 months ago Spexis announces the results of its Annual General Meeting 2023
PRESS RELEASE published on 06/07/2023 at 07:30, 3 years 4 months ago Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances
PRESS RELEASE published on 05/30/2023 at 07:15, 3 years 5 months ago Spexis provides business update and announces financial results for the full year 2022
PRESS RELEASE published on 04/28/2023 at 07:20, 3 years 6 months ago Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.
PRESS RELEASE published on 04/18/2023 at 07:15, 3 years 6 months ago Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
PRESS RELEASE published on 02/08/2023 at 07:20, 3 years 8 months ago Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
PRESS RELEASE published on 01/25/2023 at 12:56, 3 years 9 months ago Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
Published on 11/04/2026 at 22:15, 30 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 40 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/04/2026 at 15:55, 6 hours 50 minutes ago Boba Mint Outlines Planned Heatcheck Rebrand and Asset Restructuring and Announces Cease Trade Order
Published on 11/04/2026 at 15:07, 7 hours 38 minutes ago Boron One Signs Second Binding Offtake Agreement for Sale of Boron Concentrates and Refined Boron Products
Published on 11/04/2026 at 15:00, 7 hours 45 minutes ago Vox Royalty Provides Update & Timeline for Assets Entering Production
Published on 11/04/2026 at 19:41, 3 hours 3 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 3 hours 19 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 4 hours 2 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 4 hours 39 minutes ago Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 17:40, 5 hours 5 minutes ago Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.26.
Published on 11/04/2026 at 18:00, 4 hours 44 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 4 hours 44 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 5 hours 1 minute ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
